New Delhi / Mumbai: Lovid-19 Vaccine Single Dosage Johnson & Johnson has received approval of emergency use in India, to become the fifth JAB against Coronavirus to get approval in the country.
However, there is an initial uncertainty of inventory as a problem around compensation for legal obligations if severe bad events have not been resolved.
“Until now, the government does not tend to provide compensation to foreign manufacturers.
We have our own manufacturers and vaccines, there is no reason why we have to be bent,” said a senior official to Ti.
The government hopes that the ongoing talks with foreign VAX producers will cause useful resolutions.
J & J Pfizer Trails and Moderna in the US and may want to enter the Indian market.
The government expects equipment to start from around September if conversation through the company, the official said.
Initial inventory can be 3-5 doses of crore a month.
It is not clear whether J & J has reached an agreement with the government for legal issues.
J & J will supply vaccines through a pact with Indian vaccine maker E.
US companies say too early to show the timeline for inventory.
“While we hope to fulfill our shipping commitment, it’s preterm to us to speculate about our vaccine delivery time,” J & J said in a statement.
“At this time, the company only negotiated with government agencies and supranational organizations (for example, the European Commission, the African Union, GAVI / COVAX) at the central level for the procurement or purchase of vaccines.
We do not work with or through the third party for access vaccines during the Pandemic period Emergency at this time, “he said.
At present, there are no individuals or private companies authorized to offer, advertise, distribute or sell Janssen Covid-19 vaccines on behalf of J & J, both directly and indirectly, said the company.
Sources say biologically can begin local manufacturing and supply vaccine J & J in India only if the American company agrees to follow the norms of the country’s law compensation.
Considering that the only third J & J to Pfizer and modern vaccines in America, India can find as a profitable market with e biologically as a local partner.
The fact that India is also seeing increasing its vaccination coverage can also make it more feasible for J & J.
There is visibility in-principle about 5 doses of crore per month given by the company, the official source said.
If the inventory of modern or J & J starts, it will be an additional 135 crore doses that are projected supplied by the government between August and December.
The government expects the Corbevax ZY-COV-D and Biological Zydus Cadila to be approved immediately.